GlassScriptPhysician profile
Bethany L Morrell
NPI 1538594841
$6,085.91
in general payments reported to CMS, 2019-2025
31 companies · $788 in 2025
The $788 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,514 · 2022: $1,803 · 2023: $1,537 · 2024: $444 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,768.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,005.28 | 2021-2025 | |
| Amgen INC. | $936.59 | 2021-2025 | Repatha, Evenity, Prolia |
| Lilly USA, LLC | $915.50 | 2021-2024 | Zepbound, Mounjaro, Trulicity |
| Novartis Pharmaceuticals Corporation | $532.31 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $429.38 | 2021-2024 | Farxiga |
| Novo Nordisk INC | $318.89 | 2021-2025 | Wegovy |
| Amarin Pharma, INC. | $249.09 | 2021-2022 | |
| Corcept Therapeutics | $224.97 | 2021-2023 | Korlym |
| Esperion Therapeutics, INC. | $199.57 | 2021-2023 | Nexletol |
| Madrigal Pharmaceuticals | $146.22 | 2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $126.00 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.74 | 2025 | Caplyta |
| Regeneron Healthcare Solutions, INC. | $103.35 | 2021-2023 | Evkeeza |
| Exact Sciences Corporation | $82.67 | 2023-2025 | Cologuard Collection Kit |
| Antares Pharma, INC. | $74.61 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $71.87 | 2023 | Veozah |
| Glaxosmithkline, LLC. | $70.85 | 2022-2023 | Trelegy Ellipta, Shingrix |
| Biohaven Pharmaceuticals, INC. | $68.61 | 2021 | |
| Medicure Pharma INC. | $64.39 | 2021-2023 | Zypitamag |
| Idorsia Pharmaceuticals US INC | $52.14 | 2023-2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.37 | 2021-2023 | Jardiance, Tradjenta |
| Currax Pharmaceuticals LLC | $48.62 | 2024-2025 | Contrave |
| Halozyme INC | $42.89 | 2023 | |
| Clarus Therapeutics INC. | $21.85 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $21.23 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.55 | 2022 | |
| Alexion Pharmaceuticals, INC. | $19.33 | 2021 | |
| Phadia US INC. | $18.60 | 2021 | |
| Cranial Technologies, INC | $17.05 | 2023 | Doc Band |
| Amryt Pharma Holdings LTD | $15.50 | 2021 | |
| Myriad Women'S Health, INC. | $12.89 | 2023 | Myrisk |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Morrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.